Day: ខែ​កញ្ញា 2, 2025

TOKYO and CAMBRIDGE, MA, August 30, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIKTM, pronounced “I Click”) for maintenance dosing. LEQEMBI IQLIK is a subcutaneous autoinjector (SC-AI) developed by Eisai, containing 360 mg/1.8 mL (200 mg/mL) that can be administered in approximately 15 seconds. LEQEMBI IQLIK autoinjector is indicated for maintenance dosing to treat Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease(collectively referred to as early AD) in the U.S. After 18 months of LEQEMBI (lecanemab-irmb) intravenous(IV) treatment at 10 mg/kg every two weeks, patients may either c…

TOKYO, Japan, August 29, 2025 – (JCN Newswire via SeaPRwire.com) – Honda Motor Co., Ltd. (Honda) today announced new plans regarding the relocation of its global head office function:1) Honda will relocate its global head office function, before the end of 2029*, to the high-rise office floors of a new mixed-use building currently under construction near Tokyo Station, as a part of the Yaesu 2-Chome Central District Category-I Urban Redevelopment Project (“Yaesu District Redevelopment Area”).2) Honda will conduct a partial transfer of the ownership of Honda Aoyama Building (“Aoyama Bldg.”), the company’s existing head office building in Aoyama, Minato-ku, Tokyo, to Mitsui Fudosan Residential Co., Ltd.Yaesu 2-Chome Central District Category-I Urban Redevelopment ProjectPerspective drawing of exterior (Tokyo Station Yaesu Exit side)It has been 40 years since Honda built the Aoyama Bldg. as its global head office. Amid the continued rapid transformation of society and industry, Honda continues striving to be a “…

TOKYO, August 29, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has received orphan drug designation for anticancer agent the EZH2*1 inhibitor tazemetostat hydrobromide (generic name, product name “Tazverik® Tablets 200 mg”, “tazemetostat”) for unresectable INI1*2-negative epithelioid sarcoma that has progressed after chemotherapy, from the Ministry of Health, Labour and Welfare (MHLW).Epithelioid sarcoma is a type of soft tissue sarcoma that is a rare cancer estimated to account for about 1% of all soft tissue sarcoma.1 Only 174 cases were registered from major hospitals across Japan over a10-year period from 2006 to 2015.2 Loss of INI1, which is a negative regulator of EZH2, is observed in over 90% of epithelioid sarcoma cases,3 leading to EZH2 activation that is believed to drive tumor onset and malignant progression. Treatment options are limited, resulting in an extremely high unmet medical need.Tazemetostat was approved…

Completion of strategic acquisition affirms Hitachi Energy’s position as a market and technology leader in advancing energy storage innovation – a cornerstone of secure energy transitionsPower electronics with advanced digital capabilities are critical to ensure reliability and stability of the electric gridZurich, Switzerland, August 28, 2025 – (JCN Newswire via SeaPRwire.com) – Hitachi Energy, a global leader in electrification, has completed the acquisition of the remaining stake in eks Energy, a technology and market leader in power electronics and control solutions to deliver a scalable, flexible, and complete approach for energy storage customers. Hitachi Energy acquired a majority stake in eks Energy in 2023. As energy storage emerges as a cornerstone of grid stability, reliability and energy security, the IEA1 has called for a sixfold increase in global storage capacity to 1,500 GW by 2030. Underscoring this urgency, the COP29 Global Pledge2 highlights energy storage and grid infrastructure as essenti…

Massachusetts, USA, September 2, 2025 – (JCN Newswire via SeaPRwire.com) – Mitsubishi Corporation (“MC”) is pleased to announce its participation in a third-party allotment of shares by Commonwealth Fusion Systems LLC (Headquarter: Massachusetts, USA, Representative: Bob Mumgaard, “CFS”), a fusion energy start-up originating from MIT *1. This investment was made in collaboration with a consortium of 12 Japanese companies *2 (“Japanese Consortium”). In the field of fusion energy, this investment builds on MC’s previous investment in Kyoto Fusioneering Ltd., announced on May 17, 2023.*1 Massachusetts Institute of Technology*2 MC, Mitsui & Co., Ltd., Kansai Electric Power Co., Inc., JERA, Mitsui O.S.K. Lines, Ltd., JGC, Development Bank of Japan, Inc., NTT Corporation, Fujikura Corporation, Sumitomo Mitsui Banking Corporation, Sumitomo Mitsui Trust Bank, Limited, Mitsui Fudosan Co., Ltd.Fusion energy is produced when two light nuclei, typically deuterium and tritium, …

TOKYO, September 2, 2025 – (JCN Newswire via SeaPRwire.com) – Hitachi, Ltd. (TSE:6501, “Hitachi”) has been certified as a Gold Partner*1 of Scaled Agile, Inc. (“SAI”), the provider of SAFe®, the world’s most trusted system for business agility.SAFe is a management framework that supports organizational transformation and business agility, helping to enhance competitiveness and maximize customer value and is widely adopted globally. Within the Hitachi Group, GlobalLogic was certified as a Silver Partner of SAI in 2021 and has been supporting agile DX transformation based on customer experience.Amid increasingly rapid social change and growing uncertainty, Hitachi will apply SAFe as a common framework across One Hitachi to support customers globally in rapidly adapting to change and continuously creating value. For example, by applying SAFe to the implementation of “HMAX*2”, which embodies Lumada 3.0 and aims to solve customer and societal challenges by converting data into value using Hitachi’s domain know…